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Melioidosis is a severe disease that can be difficult to di-
agnose because of its diverse clinical manifestations and 
a lack of adequate diagnostic capabilities for suspected 
cases. There is broad interest in improving detection and 
diagnosis of this disease not only in melioidosis-endemic 
regions but also outside these regions because melioidosis 
may be underreported and poses a potential bioterrorism 
challenge for public health authorities. Therefore, a work-
shop of academic, government, and private sector person-
nel from around the world was convened to discuss the cur-
rent state of melioidosis diagnostics, diagnostic needs, and 
future directions.
Melioidosis is a frequently fatal infection caused by the gram-negative bacillus Burkholderia pseudomal-
lei (1). It is highly endemic to northeastern Thailand and 
northern Australia, where the causative organism is com-
monly found in soil and fresh water. Melioidosis also oc-
curs in those who travel to disease-endemic regions of the 
world, which include tropical regions of Asia and South 
America, Central America, various Pacific and Indian 
Ocean islands, and some countries in Africa (1). B. pseu-
domallei can also cause latent infection; the longest docu-
mented interval between exposure and clinical melioidosis 
is 62 years (2). The crude case- fatality rate for melioidosis 
ranges from 14% to 40% and may be as high as 80% if ef-
fective antimicrobial drugs are not given.
Clinical diagnosis of melioidosis is difficult because 
the disease has no pathognomonic clinical manifestations 
(1). The current diagnostic standard is culture; however, B. 
pseudomallei can be misidentified as a culture contaminant 
or as another species (e.g., Burkholderia cepacia, Bacillus 
spp., or Pseudomonas spp.), especially by laboratory staff 
unfamiliar with this organism (1,3–5). In addition, B. pseu-
domallei is categorized as a Tier 1 select agent by the US 
government, and special precautions are recommended to 
reduce the possibility of exposure while conducting bacte-
rial culture. There are currently no commercially available 
and reliable rapid diagnostic tests for melioidosis. Serologic 
tests, such as indirect hemagglutination assay (IHA), have 
been widely used, but these are neither sensitive nor specific.
With the goal of improving timely and accurate di-
agnosis of melioidosis, a workshop sponsored by the US 
Centers for Disease Control and Prevention was held in 
Bangkok, Thailand, on September 14–15, 2013, to discuss 
current recommendations and future research directions. 
International subject matter experts representing academia, 
government, and the private sector attended the workshop 
to discuss the current state of melioidosis diagnostics, diag-
nostic needs, and future directions. The workshop consisted 
of multiple sessions focused on specific diagnostic topics 
(e.g., culture, PCR, serology, and new methods). Each ses-
sion included short presentations followed by extensive 
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group discussions. Notes from these group discussions 
along with correspondence exchanged shortly after the 
workshop were used to clarify points and reach consensus. 
This article provides a workshop summary as an informa-
tive diagnostic guide for clinicians and laboratory staff.
Optimal Diagnostic Workup for Patients with  
Suspected Melioidosis
Clinical manifestations of melioidosis vary widely and can 
include sepsis with or without a localized infection such 
as pneumonia or internal organ abscesses. Chronic disease 
(symptoms >2 months) can occur and can mimic other dis-
eases such as tuberculosis or cancer. Therefore, melioidosis 
should be suspected for every patient with community-ac-
quired sepsis, pneumonia, or abscesses, from areas where 
indigenous melioidosis cases have been reported. In non–
meliodisis-endemic regions, such as the United States and 
Europe, a diagnosis of melioidosis should be considered for 
every patient with sepsis and a history of having traveled to 
melioidosis-endemic regions, especially for those with pre-
disposing conditions such as diabetes mellitus, renal dis-
ease, or immunosuppression. Because the duration of latent 
infection can extend for decades (2), a complete travel his-
tory should be obtained. In addition, patients with no his-
tory of having traveled outside non–melioidosis-endemic 
regions but who have been exposed to imported animals, 
soil, or plants might also be at risk for B. pseudomallei in-
fection (6,7), albeit rarely.
Blood culture should be performed for all patients with 
suspected melioidosis, and urine and throat swab samples 
should be obtained and cultured by using selective media, 
even for patients without pharyngitis or urinary symptoms 
(8–11). Sputum samples, swab samples from surface le-
sions, and aspirates of pus should be collected from pa-
tients with pneumonia, localized lesions, or abscesses and 
should be cultured by using selective media. Culture of rec-
tal swab samples in selective broth may also be useful (12). 
The sensitivity of urine culture is enhanced by centrifuging 
and culturing the pellet (13). Clinicians should notify labo-
ratories when melioidosis is suspected so laboratory scien-
tists can perform appropriate testing and use appropriate 
biosafety practices to prevent laboratory exposure (3,14).
B. pseudomallei is able to survive for long periods in 
moist environments, although it survives less well at low 
temperatures (15,16). Although the organism may survive 
desiccation, viability may be compromised (17). There-
fore, clinical samples should be transported to the labora-
tory at room temperature and processed as soon as pos-
sible, and swabs should preferably be placed in a suitable 
transport medium.
In humans, B. pseudomallei does not form part of the 
normal colonizing microbiota; growth of the organism 
from any site is diagnostic (9). Persistently positive cultures 
without apparent clinical disease have been described for a 
few patients with cystic fibrosis or bronchiectasis; howev-
er, even in these settings an attempt at eradication is worth-
while (18–21). Specimens are often culture positive even 
those from patients pretreated with effective antimicrobial 
drugs (22). In our collective experience, negative cultures 
obtained after a full diagnostic workup for patients unlikely 
to have melioidosis provide generally sufficient reason to 
cease broad-spectrum antimicrobial drugs (e.g., a carbape-
nem or ceftazidime) after 4–7 days. For patients with signs 
strongly suggestive of melioidosis, repeating all cultures on 
multiple occasions and searching for occult foci of infec-
tion (e.g., abscesses in liver, spleen, or urinary tract, includ-
ing the prostate gland) with imaging is recommended.
Culture and Identification
Although culture is the diagnostic standard and is 100% 
specific, sensitivity may be as low as 60%, depending on 
the method of sample collection, media used, and expertise 
of the microbiologist (23). Because many samples from pa-
tients with suspected melioidosis are collected from non-
sterile sites, the use of selective media is critical. Ashdown 
agar is commonly used in areas where melioidosis is en-
demic and is cost-effective (24), but it is not commercial-
ly available in most countries. Alternative media that are 
more commonly available are B. cepacia selective agar and 
Pseudomonas cepacia agar (11,25). The B. pseudomallei 
load in clinical samples can vary greatly and is particularly 
low in blood (0.1–100 CFU/mL); the highest concentration 
is usually in sputum (102–109 CFU/mL) (26).
B. pseudomallei colonies are usually cream colored 
with a metallic sheen and may become dry and have a matte 
or wrinkled appearance after incubation for >24 hours on 
blood agar, although considerable variation is seen. On 
MacConkey agar, B. pseudomallei colonies are pale (lac-
tose nonfermenters) and may exhibit a metallic sheen and 
become pink and umbonate or rugose after 48 hours. On tri-
ple sugar iron agar, B. pseudomallei may indicate either no 
change or slight oxidation. Nonetheless, the morphologic 
appearance of bacterial colonies on common culture media 
may also be atypical. The demonstration of typical colonies 
on Ashdown agar after prolonged incubation (48–96 hours) 
and the appearance of a pellicle in Ashdown broth add sup-
port where this medium is available (8,27). Gram-stained 
B. pseudomallei may not resemble the textbook description 
of having bipolar staining (“safety pin” appearance). The 
microscopic morphology of organisms from patients re-
ceiving antimicrobial drugs may be highly atypical, may be 
filamentous, or may appear similar to that of yeasts (28). B. 
pseudomallei is readily dismissed as a culture contaminant 
or misidentified as Pseudomonas spp. or other organisms 
when standard identification methods are used, including 
API 20NE (bioMérieux, Craponne, France) and automated 
bacterial identification systems (Table 1). In areas where 
B. pseudomallei is uncommonly encountered, it may be 
overlooked. B. pseudomallei colonies may resemble con-
taminants (e.g., Pseudomonas stutzeri also forms wrinkled 
colonies) and be discarded erroneously. Therefore, it is 
strongly recommended that any non–Pseudomonas aeru-
ginosa, oxidase positive, gram-negative bacillus isolated 
from any clinical specimen should be suspected to be B. 
pseudomallei (39). In addition, an antibiogram may be use-
ful for identification of oxidase-positive, gram-negative 
bacilli; B. pseudomallei is typically resistant to aminogly-
cosides (e.g., gentamicin), colistin, and polymyxin but sus-
ceptible to amoxicillin/clavulanic acid (40).
Latex agglutination is particularly useful as a rapid di-
agnostic test for the identification of B. pseudomallei isolates 
grown on solid agar or liquid culture or directly on blood cul-
ture fluid. The latex agglutination reagent developed in Thai-
land, based on a monoclonal antibody specific to a 200-kDa 
exopolysaccharide, has a sensitivity of 95.1% and specificity 
of 99.7% on blood culture fluid (41). Several other latex ag-
glutination assays that use monoclonal or polyclonal anti-
bodies developed in house have been described; however, 
comparative performance of these assays in routine clinical 
practice has not been undertaken to date (39,42,43). The use 
of a validated, specific latex agglutination reagent is suffi-
cient for identifying isolates suspected to be B. pseudomallei 
on the basis of the microbiological characteristics described 
above. Any atypical isolates that are potentially B. pseudom-
allei, and the first such isolates from any geographic region, 
should ideally undergo further confirmatory testing. Latex 
agglutination in particular fulfills many of the characteris-
tics of a useful test; it is rapid (<5 minutes), simple to learn, 
and inexpensive; results are reproducible and accurate. It can 
enable technicians in local microbiology facilities in devel-
oping countries to identify B. pseudomallei effectively. We 
support initiatives to improve the availability of such a test 
worldwide, which ideally could be used to screen all suspect 
B. pseudomallei originating from clinical specimens.
In general, commercially available identification sys-
tems (e.g., API 20NE, Phoenix [Becton, Dickinson and 
Company, Franklin Lakes, NJ, USA], and VITEK [bio-
Mérieux]) perform adequately (Table 1). Fresh cultures 
should be used for biochemical testing, and it is important 
to note the apparent regional variation in performance of 
some identification kits (30). The API 20NE correctly iden-
tified 98%–99% of B. pseudomallei isolates in Thailand but 
identification was highly variable (37%–98%) in Australia, 
where B. pseudomallei was commonly misidentified as B. 
cepacia or Chromobacterium violaceum (27,30,31,33,44). 
In addition, isolates from Malaysia are more commonly 
misidentified because they are poorly represented in bio-
chemical profile databases and may be susceptible to gen-
tamicin, issues that could be important when considering 
strains from other locations (38). Misidentification may 
lie with the interpretation of assimilation tests, which can 
be difficult to read when using API 20NE (33). Previous 
reports showed that VITEK 1 correctly identified 99% of 
B. pseudomallei isolates. The fluorometric-based ID–gram-
negative bacillus card of the VITEK 2 correctly identified 
only 19% of B. pseudomallei in 2002, but a newer colo-
rimetric-based GN (gram-negative) card identified 63%–
81% of B. pseudomallei correctly, depending on the culture 
media used (30,36). Automated systems accuracy relies on 
the size of the strain database used for identification.
Where reference laboratories are available, defini-
tive species identification is possible by PCR with use of 
a variety of published systems such as TTS1, BurkDiff, 
and others (45–47). The Laboratory Response Network 
Burkholderia spp. real-time PCR assay is also available in 
laboratories participating in the Network (48). Laboratories 
with sequencing capabilities may also consider using 16S 
rRNA gene sequencing (49).
Disk-diffusion susceptibility testing is routinely used 
in melioidosis-endemic areas, although as yet no interpreta-
tive criteria have been published by the Clinical and Labora-
tory Standards Institute, which recommends measurement 
 
Table 1. Performance of commercially available systems for identification of Burkholderia pseudomallei 
Method Isolate source B. pseudomallei, no. correct/no. tested (%) Reference 
API 20 NE* Thailand 390/400 (98) (27) 
API 20 NE Singapore 40/50 (80) (29) 
API 20 NE Australia 101/103 (98) (30) 
API 20 NE Australia 26/71 (37) (31) 
API 20 NE United States (imported) 35/58 (60) (32) 
API 20 NE Thailand/various 792/800 (99) (33) 
Phoenix† Singapore 13/47 (28) (34) 
Phoenix Malaysia/Thailand 0/1 (0) (35) 
VITEK 2* Australia 19/103 (19) (30) 
VITEK 2 Australia 83/103 (81) (36) 
VITEK 2 Malaysia 0/1 (0) (37) 
VITEK 2 Australia 146/149 (98) (38) 
VITEK 2 Sabah, Malaysia 22/25 (88) (38) 
VITEK 2 Sarawak, Malaysia 23/43 (53) (38) 
*bioMérieux, Craponne, France. 
†Becton, Dickinson, and Company, Franklin Lakes, NJ, USA. 
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of MICs for B. pseudomallei (50). A specific issue arises 
when performing antimicrobial drug–susceptibility test-
ing for co-trimoxazole, a first-line antimicrobial drug used 
in the eradication phase of melioidosis treatment. Testing 
should use a MIC-based method because the disk-diffusion 
method overestimates resistance (51–53). Graduated anti-
biotic strips (Etests) may be used but are sometimes dif-
ficult to read because of the “double zone,” a phenomenon 
that occurs when combination antimicrobial drug formula-
tions are tested.
Rapid Detection of B. pseudomallei in  
Clinical Specimens
Several assays that can be used for direct detection of B. 
pseudomallei in clinical specimens have been developed 
and include an immunofluorescence assay (IFA), PCRs, 
and a lateral flow immunoassay (LFI). In addition, these 
tests can be used for the identification of B. pseudomallei 
isolates grown on solid agar or in liquid culture.
The IFA is rapid, simple, and reliable and uses a mono-
clonal antibody against capsule polysaccharide (CPS) to de-
tect B. pseudomallei directly in clinical specimens or from 
blood culture bottles (28,54). It is particularly useful for 
specimens in which bacterial density is at least 103 CFU/
mL (e.g., in pus, sputum, and urine) (28). Although cul-
ture results may take 1–7 days, IFA takes only 15 minutes. 
However, IFA requires a UV microscope and experienced 
technicians, and the diagnostic sensitivity of IFA (range 
45%–66%) is lower than that of culture (28,55). Although 
IFA is not commercially available, it has a long, positive 
track record of use in some specialized laboratories for pro-
viding rapid diagnosis in melioidosis-endemic regions.
Nucleic acid detection methods could shorten the time 
to diagnosis. Several PCRs have been developed and evalu-
ated, including conventional and real-time PCRs; the latter 
PCR is more rapid and sensitive. Some assays detect B. 
pseudomallei exclusively, whereas others are designed in 
multiplex formats to identify B. pseudomallei and differ-
entiate it from close relatives such as Burkholderia mal-
lei or Burkholderia thailandensis (45). To date, these as-
says have been useful for identifying isolates (47,56), but 
their performance in testing DNA extracted directly from 
specimens has been variable, and they are not routinely 
used in melioidosis-endemic regions (31,47,56–58). Some 
specimens (e.g., sputum) are more likely to yield a positive 
result than are others (e.g., blood), probably because of dif-
fering bacterial concentrations in these specimens (57–59).
An LFI has been developed that uses a monoclonal 
antibody specific to CPS similar to that used in the latex 
agglutination test (60). The assay has been shown to work 
with various types of clinical specimens routinely collected 
from patients with suspected melioidosis and to identify the 
organism isolated from solid and liquid media. Sensitivity 
and specificity of the LFI have been evaluated on 77 diverse 
B. pseudomallei isolates and 36 near-neighbor species and 
were 98.7% and 97.2%, respectively. A single atypical iso-
late that had a mutation reported to affect CPS expression 
produced a false-negative result, and a single B. thailand-
ensis isolate that had the CPS biosynthetic operon and ex-
presses capsule produced a false-positive result (20,60,61). 
Most B. thailandensis strains do not have this operon; in 
addition, this species is not typically associated with infec-
tions and is thus unlikely to cause false-positive results in 
the clinical laboratory (61). This test has the potential for 
use as a rapid diagnostic test for B. pseudomallei identifica-
tion worldwide.
Serologic Tests
The IHA is the main serologic assay used worldwide, al-
though it lacks standardization. The diagnostic sensitiv-
ity of the IHA at admission is only 56%, and the variable 
prevalence of background seropositivity in areas where 
melioidosis is endemic reduces its specificity (62–64). As a 
result, the IHA has no role in the diagnosis of melioidosis 
in disease-endemic regions, and its use should be discour-
aged. The IHA may be of value during the evaluation of 
febrile illness in travelers who have not lived in but have 
traveled to a melioidosis-endemic region. A negative result 
does not rule out melioidosis, but a positive result implies 
exposure to B. pseudomallei (65). The IHA is also useful 
in non–melioidosis-endemic areas for potentially exposed 
laboratory workers or military personnel (3,66). Although 
a 4-fold rise in IHA titer has been used as evidence of meli-
oidosis infection, this finding is not sufficiently sensitive 
or specific enough to guide treatment decisions in melioi-
dosis-endemic areas. Similarly, although titers might wane 
after treatment, a persistently high IHA titer does not nec-
essarily indicate treatment failure or latent infection (62).
Other serologic assays, including in-house tests using 
ELISA, have been developed (67). However, development 
and evaluation of serologic tests have been hampered by 
the low sensitivity of the diagnostic standard (i.e., culture) 
(23,68). ELISA is a much less labor-intensive assay for 
some applications. Work with latent class statistical models 
has raised the possibility that culture is an imperfect diag-
nostic standard (23). This finding has prompted reevalu-
ation of older serologic assays (68) and has implications 
for the evaluation of new diagnostic tests (69). Tools for 
analyzing diagnostic test data where there are no diagnos-
tic standards have been made available online (http://mice.
tropmedres.ac) (70). In addition, new serologic assays that 
use polysaccharides purified from B. pseudomallei, such as 
O-antigen polysaccharide and CPS, are being developed. 
These tests have the potential to be the next generation 
of serologic assays and will enable greater standardiza-
tion. Multiplex assays are also being developed to detect 
B. pseudomallei antigens and antibody in combination with 
tests for other pathogens.
Future Diagnostic Tests
Matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF) is increasingly be-
ing used as a rapid method for isolate identification. This 
method requires comparison of mass spectroscopy profiles 
against a database of isolates belonging to known species. 
There are 2 types of database: a closed database for which 
the fidelity of isolates is verified by the manufacturer and 
an open database to which isolates are added locally. The 
performance of MALDI-TOF is hampered by the sparse 
number of isolate profiles in current closed databases (71). 
Efforts to add B. pseudomallei isolates to local open da-
tabases are under way in some melioidosis-endemic ar-
eas, but their provenance must be clear. Addition of these 
isolates to closed proprietary databases would make them 
more useful outside melioidosis-endemic areas. Although 
there is a proliferation of new species within the genus Bur-
kholderia for which no profiles exist on MALDI-TOF data-
bases, the clinical significance of these species is borderline 
because few are associated with clinical disease.
MALDI-TOF methods are also being used to detect 
unique metabolite signatures present in patients with meli-
oidosis. Preliminary work indicates that the metabolome of 
patients with melioidosis can be differentiated from that of 
patients with sepsis from other causes. The identification 
of such metabolites could lead to the development of rapid 
assays for their specific detection.
Also being developed are rapid antimicrobial drug–
susceptibility testing methods that use quantitative PCR to 
rapidly evaluate susceptibility by comparing the growth of 
bacteria exposed to varying concentrations of antimicrobial 
drugs with that of unexposed bacteria. These methods are 
being developed as part of bioterrorism preparedness initia-
tives in the United States to ensure rapid and appropriate 
responses. According to preliminary work, the results are 
available up to 12 hours sooner and seem to correlate with 
conventional broth microdilution results for many, but not 
all, clinically relevant antimicrobial drugs. This approach 
has been used successfully for Bacillus anthracis (72).
Misconceptions and Pitfalls when  
Diagnosing Melioidosis
In many regions of the world, the lack of microbiology labo-
ratories hampers the diagnosis of bacterial infections in gen-
eral, including melioidosis. Nonetheless, where microbiolo-
gy facilities exist, identification of patients with melioidosis 
can still be problematic because of the lack of awareness 
among clinicians and laboratory staff, including lack of 
awareness of low-level endemicity where indigenous cases 
 
 
Table 2. Common misconceptions and pitfalls in the identification of Burkholderia pseudomallei and diagnosis of melioidosis 
Misconception or pitfall Comments 
Melioidosis is endemic only to some parts of Asia and northern 
Australia. 
Melioidosis is reported in many regions of the world, including 
regions of Central and South America, various Pacific and Indian 
Ocean islands, and some countries in Africa. 
Melioidosis is not endemic to the area because B. pseudomallei 
has never been reported from the microbiological facilities. 
B. pseudomallei can be misidentified as another Burkholderia 
species, Pseudomonas spp., or other organisms, especially by 
laboratory staff unfamiliar with B. pseudomallei. 
Melioidosis is only an acute, septic illness. 10%–15% of patients have chronic disease that may mimic other 
conditions, including tuberculosis. 
Lifetime travel history to non–melioidisos-endemic areas is not 
taken. 
Melioidosis may appear many years after exposure. 
Do not provide treatment for melioidosis unless any diagnostic 
test is positive. 
Melioidosis is often fatal, and treatment effective against B. 
pseudomallei should be provided immediately if melioidosis is 
suspected. 
Throat swab and urine specimens should be collected only from 
patients with symptoms of pharyngitis or urinary tract infection. 
Swabs of throat (anterior fauces) or urine may be positive in 
patients without focal symptoms. 
Culture is a sensitive method for diagnosing melioidosis. As with most infections, the sensitivity of culture depends on the 
quality of the specimen, and deep, occult sites of infection are also 
possible. 
Indirect hemagglutination assay is a reliable diagnostic test. Sensitivity and specificity of indirect hemagglutination assay is poor. 
B. pseudomallei can be a colonizing organism. Although chronic infection after treatment has been described, 
isolation of B. pseudomallei from any body site should be regarded 
as indicative of disease. 
Selective media for B. pseudomallei are not necessary. Sensitivity of culture is lower and the diagnosis would be missed for 
many patients if selective media are not used for specimens from 
nonsterile sites. 
The “safety pin” appearance is a reliable characteristic of gram-
stained B. pseudomallei. 
B. pseudomallei usually stains unevenly but is not always bipolar, 
whereas other organisms such as Eshcherichia coli or Klebsiella 
spp. may appear bipolar with gram stain. 
Automated microbiology systems can reliably detect B. 
pseudomallei. 
Although these systems are generally reliable, misidentification is 
not uncommon, particularly in regions where few strains are 
included in phenotypic databases. 
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have been described (e.g., in India and Brazil) and failure to 
elicit or communicate a history of travel from patients re-
turning from melioidosis-endemic areas. Table 2 describes 
common misconceptions and pitfalls that can occur when 
diagnosing melioidosis; the Figure illustrates when to sus-
pect melioidosis, what specimens to take, and what types of 
tests are available.
Challenges in Various Settings
In melioidosis-endemic areas, if melioidosis is suspect-
ed, empiric treatment with antimicrobial agents effective 
against B. pseudomallei should be initiated immediately, 
before diagnostic results are available, in an effort to re-
duce the number of deaths. Diagnostic tests used in melioi-
dosis-endemic areas should be able to confirm melioidosis 
with high accuracy, with high positive and negative predic-
tive values. High positive and negative predictive values 
are essential if the test result is being used to determine 
whether melioidosis-specific antimicrobial agents (rather 
than broad-spectrum empirically used antimicrobial agents 
to cover melioidosis-specific and other pathogenic organ-
isms) are appropriate and whether the patients need to be 
treated with prolonged oral therapy to prevent melioidosis 
relapse. A rapid test that could be used at the point of care 
would be most useful in melioidosis-endemic areas. The 
ideal rapid test should use inexpensive commonly avail-
able equipment, supplies, and reagents. It should require 
minimal training, be robust in a variety of laboratory con-
ditions (temperature, humidity), and have a long shelf life. 
It should be accurate and reliable even when performed on 
direct specimens, to minimize the hazard of working with 
pure culture.
In areas where melioidosis is less common or in non–
melioidosis-endemic areas, empiric antimicrobial therapy 
for acute sepsis may not include drugs active against B. 
pseudomallei. In addition, the positive predictive values 
of rapid tests are probably much lower because of the 
low-prevalence setting. Therefore, diagnostic tests devel-
oped for these regions should focus on methods that detect 
pathogens more broadly and include B. pseudomallei, such 
Figure. Diagnostic guidelines for clinicians and microbiologists in developed countries and resource-limited settings. 1The antimicrobial 
drug–susceptibility pattern can be useful for distinguishing Burkholderia pseudomallei (usually resistant to aminoglycosides and colistin or 
polymyxin but susceptible to amoxicillin/clavulanic acid) from other pathogenic species. However, isolates can occasionally be susceptible 
to aminoglycosides; susceptibility may vary by region (40). If disk diffusion is used, zone diameter interpretation may need to be modified 
from break points recommended for Enterobacteriaceae by the Clinical and Laboratory Standards Institute (73). 2Not currently commercially 
available. API 20NE, bioMérieux, Craponne, France; VITEK, Becton, Dickinson, and Company, Franklin Lakes, NJ, USA.
as 16S sequencing or multiplexed real-time PCR assays. A 
combination of antigen and antibody detection to provide 
high specificity and sensitivity might be a possible solution 
for this setting. Educating technicians and clinicians about 
diagnosis of melioidosis is also necessary. Reporting of 
cases that occur in areas where melioidosis is less common 
or in non–melioidosis-endemic areas might help familiar-
ize technicians and clinicians with this pathogen and alert 
public health officials to potential outbreaks.
Conclusions
The timely and accurate diagnosis of melioidosis is needed 
to ensure that effective antimicrobial therapy is initiated or 
continued appropriately. Distinct diagnostic obstacles exist 
in settings where melioidosis is or is not endemic and in en-
vironments with low or high levels of resources. Common 
misconceptions and pitfalls relating to diagnostic microbi-
ology can also hinder early detection. Efforts to culture B. 
pseudomallei from persons suspected to have melioidosis 
are paramount and should include culturing of all available 
specimens by using selective media such as Ashdown agar 
or B. cepacia agar. The need to make latex agglutination test-
ing available for rapid identification of isolates, particularly 
in low-resource melioidosis-endemic areas, received wide-
spread support. Simple point-of-care tests such as the LFI 
may become available in the near future and would enable 
rapid identification of isolates and direct detection in clinical 
specimens. This capacity will greatly aid rapid diagnosis in 
developed countries and in low-resource settings.
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